

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 July 2023 (13.07.2023)



(10) International Publication Number
WO 2023/131098 A3

(51) International Patent Classification:

C12N 15/113 (2010.01) A61P 31/20 (2006.01)
A61K 31/7115 (2006.01) C07H 21/00 (2006.01)

(21) International Application Number:

PCT/CN2023/000030

(22) International Filing Date:

10 January 2023 (10.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/298,092 10 January 2022 (10.01.2022) US

(71) Applicant: **AUSPER BIOPHARMA CO., LTD.**
[CN/CN]; Building 5, Room 2501, 688 Binan
Road, Binjiang District, Hangzhou, Zhejiang 310052 (CN).

(72) Inventors: **CHENG, Guofeng**; 705 Prescott Lane Foster,
California 94404 (US). **YANG, Cheng Yong**; 730 Tender
Lane Foster, California 94404 (US).

(74) Agent: **WU, FENG & ZHANG**; 3FL, Building 4, Yard 38,
Linfengerlu Road, Greenland Central Square, Haidian Dis-
trict, Beijing 100089 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION

(57) Abstract: Provided is a chimeric antisense compound comprising a modified oligonucleotide comprising 5' W1-G1-S1-G2-W2 3', wherein: W1 is a 5' wing segment, W2 is a 3' wing segment, G1 is a first gap segment, S1 is a first separator segment, and G2 is a second gap segment. Also provided is a method for decreasing HBV mRNA, DNA and protein expression. Such compounds and methods are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.

WO 2023/131098 A3